| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada [T. K., L. G., A. So., A. Sc., E. P. D.]; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, M5G 1L5, Canada [T. K., E. P. D.]; Clinical Research Unit, Department Obstetrics and Gynecology, Technical University of Munich, Munich, Germany [N. H., B. S., J. D., M. S.]; and Department of Nephrology and Internal Medicine, Medical University, Bialystok, Poland [M. M.]
Human kallikrein 8 (hK8; neuropsin) is a serine protease and new member of the hK family. The aim of this study was to examine if hK8 may serve as a novel cancer biomarker. An hk8-ELISA, developed in-house, was used to study the distribution of hK8 in various biological fluids and tissue extracts from healthy individuals and ovarian cancer patients of different stages of the disease (International Federation of Obstetrics and Gynecology II–IV). For ovarian cancer patients, very high levels in ascites fluid were observed (
1000 µg/liter; n = 85 samples). Elevated serum levels were seen in 24 of 40 (62%) of ovarian cancer patients. Higher ascites fluid hK8 concentration was associated with better ovarian cancer progression-free survival (P = 0.02). In both serum and ascites fluid, there is a significant correlation between hK8 and CA125 concentration (r = 0.51 and 0.58, respectively). The serum concentration of hK8 was an indicator of progression on regression on longitudinal monitoring of an ovarian cancer patient. These data suggest that hK8 protein is detectable in ovarian cancer tissue extracts, serum, and ascites fluid, indicating that it may serve as a new ovarian cancer marker.
This article has been cited by other articles:
|
|
 |
|
  D. Korbakis, A. K. Gregorakis, and A. Scorilas Quantitative Analysis of Human Kallikrein 5 (KLK5) Expression in Prostate Needle Biopsies: An Independent Cancer Biomarker Clin. Chem., May 1, 2009; 55(5): 904 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kuk, V. Kulasingam, C. G. Gunawardana, C. R. Smith, I. Batruch, and E. P. Diamandis Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers Mol. Cell. Proteomics, April 1, 2009; 8(4): 661 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. McIntosh, Y. Liu, C. Drescher, N. Urban, and E. P. Diamandis Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma Clin. Cancer Res., August 1, 2007; 13(15): 4422 - 4428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dorn, M. Schmitt, R. Kates, B. Schmalfeldt, M. Kiechle, A. Scorilas, E. P. Diamandis, and N. Harbeck Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients Clin. Cancer Res., March 15, 2007; 13(6): 1742 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-P. Sher, C.-C. Chou, R.-H. Chou, H.-M. Wu, W.-S. Wayne Chang, C.-H. Chen, P.-C. Yang, C.-W. Wu, C.-L. Yu, and K. Peck Human Kallikrein 8 Protease Confers a Favorable Clinical Outcome in Non-Small Cell Lung Cancer by Suppressing Tumor Cell Invasiveness Cancer Res., December 15, 2006; 66(24): 11763 - 11770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.R. Darling, L. Jackson-Boeters, T.D. Daley, and E.P. Diamandis Human Kallikrein 6 Expression in Salivary Gland Tumors J. Histochem. Cytochem., March 1, 2006; 54(3): 337 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Borgono, T. Kishi, A. Scorilas, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1487 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Simon, S. Zhuo, L. Corral, E. P. Diamandis, M. J. Sarno, R. L. Wolfert, and N. W. Kim B7-H4 Is a Novel Membrane-Bound Protein and a Candidate Serum and Tissue Biomarker for Ovarian Cancer Cancer Res., February 1, 2006; 66(3): 1570 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nagahara, K. Mimori, T. Utsunomiya, G. F. Barnard, M. Ohira, K. Hirakawa, and M. Mori Clinicopathologic and Biological Significance of Kallikrein 6 Overexpression in Human Gastric Cancer Clin. Cancer Res., October 1, 2005; 11(19): 6800 - 6806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Borgono, L. Grass, A. Soosaipillai, G. M. Yousef, C. D. Petraki, D. H. C. Howarth, S. Fracchioli, D. Katsaros, and E. P. Diamandis Human Kallikrein 14: A New Potential Biomarker for Ovarian and Breast Cancer Cancer Res., December 15, 2003; 63(24): 9032 - 9041. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
